Masatsugu Shiba

Masatsugu Shiba

Auto-generated profile, based on publicly available information

Masatsugu Shiba

Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
YNYasuaki Nagami
Yasuaki Nagami
MOMasaki Ominami
Masaki Ominami
MSMasatsugu Shiba
Masatsugu Shiba
HMHiroaki Minamino
Hiroaki Minamino
SFShusei Fukunaga
Shusei Fukunaga
TATetsuo Arakawa
Tetsuo Arakawa

13 October 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
RURisa Uemura
Risa Uemura
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
NINarika Iwakura
Narika Iwakura
MSMasatsugu Shiba
Masatsugu Shiba
KWKenji Watanabe
Kenji Watanabe
TATetsuo Arakawa
Tetsuo Arakawa
Several studies have reported a significant association between sleep disturbance and inflammatory bowel disease (IBD). The aim of the present study is to compare the clinical characteristics and the health-related quality of life (HR-QOL) of Japanese IBD patients with or without sleep disturbances, and to investigate the risk factors for disease flare in these patients. IBD patients were asked to complete a self-administered questionnaire including the Pittsburg sleep quality index and the 8-item short-form health survey. The information about disease flare within 1 year from enrollment in the study was analyzed with a multiple logistic regression model to identify risk factors for IBD flare-ups. The prevalence of sleep disturbances was 44.1 % (60 out of 136 IBD patients). Use of sleep medications was significantly higher in IBD patients with sleep disturbances whereas use of immuno modulators was significantly higher in IBD patients without sleep disturbances. The scores from all HR-QOL domains were significantly lower in patients with sleep disturbances than in patients without sleep disturbances. Fifty-one patients (37.5 %) had disease flare within 1 year from enrollment in the study and sleep disturbances were identified as a significant risk factor for disease flare (OR 3.09, 95 % CI 1.47–6.43). Our results indicate that sleep disturbances are common in Japanese IBD patients and are associated with poorer HR-QOL. Since the presence of sleep disturbances is a significant risk factor for IBD flare-ups, we encourage physicians to perform a careful examination of sleep disturbances in IBD patients.

1 December 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MKMakiko Kaji
Makiko Kaji
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
MSMasatsugu Shiba
Masatsugu Shiba
YKYukie Kohata
Yukie Kohata
HYHirokazu Yamagami
Hirokazu Yamagami
TATetsuo Arakawa
Tetsuo Arakawa

3 April 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MYMasanori Yamato
Masanori Yamato
TWToshio Watanabe
Toshio Watanabe
KHKazuhide Higuchi
Kazuhide Higuchi
KTKoichi Taira
Koichi Taira
TTTetsuya Tanigawa
Tetsuya Tanigawa
TATetsuo Arakawa
Tetsuo Arakawa

14 November 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YNYuji Nadatani
Yuji Nadatani
TWToshio Watanabe
Toshio Watanabe
TTTetsuya Tanigawa
Tetsuya Tanigawa
MSMitsue Sogawa
Mitsue Sogawa
HYHirokazu Yamagami
Hirokazu Yamagami
TATetsuo Arakawa
Tetsuo Arakawa
Background. Low-dose aspirin (LDA) is the most commonly prescribed antiplatelet agent for prevention of cardiovascular events following percutaneous coronary intervention (PCI). Long-term treatment with LDA has serious adverse effects, including gastrointestinal (GI) hemorrhage. Most studies have focused only on upper GI bleeding and few studies have evaluated the effect of LDA on total GI bleeding. Aims. The aims of this study were to investigate the incidence and risk factors of total GI bleeding within 30 days after PCI in Japanese patients taking LDA. Methods. A retrospective chart review was conducted for 364 patients undergoing LDA therapy following PCI at Osaka City University Hospital. A retrospective case-control study evaluated risk factors using the chi-squared test and logistic regression. Results. The incidence of total GI bleeding after PCI within 30 days was 4.3%. The source of the GI bleeding was located throughout the GI tract. Risk factors identified by univariate analysis were age ≥75 years, history of peptic ulcer disease, chronic renal failure, proton pump inhibitor use, and histamine H2 receptor antagonist use. By multivariate logistic regression only age ≥75 years (odds ratio = 5.26; 95% confidence interval: 1.13–24.51; p = 0.035) was found to be an independent risk factor of GI bleeding. Conclusions. The incidence of GI bleeding in patients undergoing LDA therapy following PCI is high. The bleeding episodes were located in the upper, middle, and lower GI tract. Age of ≥75 years was an independent risk factor for GI bleeding after PCI in patients on LDA therapy.

1 October 2005 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
TWToshio Watanabe
Toshio Watanabe
KHKazuhide Higuchi
Kazuhide Higuchi
KTKoichi Taira
Koichi Taira
ESEiji Sasaki
Eiji Sasaki
MSMasatsugu Shiba
Masatsugu Shiba
TATetsuo Arakawa
Tetsuo Arakawa